Skip to content
Onyx Biotec logo

Onyx Biotec

ONYX NSE
₹36.00

Close ·

View as Markdown
MCP
Close 28 Oct 2026 ₹36.00 −3.00 −7.69% 1Y
Start ₹39.00

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · TTM

ROCE
1.15%
Debt to Equity
0.27
EPS (TTM)
—
Book Value
₹30.56
Market Cap
—
P/E (TTM)
—
P/B
1.18
ROE
−0.38%
Dividend Yield
0.00%
EBITDA
₹3.80 Cr
52W High
₹49.65
52W Low
₹24.20

Peer Comparison

Healthcare › Pharmaceuticals

Onyx Biotec peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Onyx Biotec (this company)
₹36.00—₹65 Cr1.180.00%−0.38%1.15%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%16.25%16.65%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

34 Poor

Data confidence 81/100

surveillance:ESM1

Category scores

Quality
28
Poor
Returns, margins, earnings quality 22% weight
Valuation
44
Weak
Cheap vs sector & own history 24% weight
Growth
54
Average
Sales & profit trajectory 9% weight
Financial Health
33
Poor
Solvency, leverage, coverage 9% weight
Momentum
56
Good
Trend strength, vol-adjusted 12% weight
Ownership
21
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

2
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 6.12% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1234
OscillatorsBullish234
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
41.43
Neutral
MACD (12,26,9)
−0.68
Bearish
SMA (50)
39.23
Bearish
SMA (200)
36.82
Bearish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+20.72%
1Y+12.14%

Net profit

Net profit growth by window
3YTurned to loss
1YTurned to loss

Operating cash flow

Operating cash flow growth by window
3YTurned negative
1YTurned negative

Operating margin· change in pp

Operating margin growth by window
3Y−6.49 pp
1Y−11.85 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2022₹44.86 Cr
Mar 2023₹39.49 Cr
Mar 2024₹53.75 Cr
Mar 2025₹61.95 Cr
Mar 2026₹69.47 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2022₹3.35 Cr
Mar 2023₹1.84 Cr
Mar 2024₹3.63 Cr
Mar 2025₹4.95 Cr
Mar 2026−₹0.21 Cr

Half-yearly Results

₹ Cr
ONYX half-yearly results, ₹ crore
Particulars Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
23.89
29.86
30.15
31.8
34.59
34.88
Expenses
20.47
24.95
24.44
27.17
33.65
32.43
Operating Profit
3.42
4.91
5.71
4.63
0.94
2.45
OPM %
14.32%
16.44%
18.94%
14.56%
2.72%
7.02%
Other Income
0.04
0.09
0.99
0.18
0.24
0.21
Interest
0.83
1.27
1.36
0.62
0.55
0.66
Depreciation
0.73
1.14
1.53
1.51
1.56
1.49
PBT
1.9
2.59
3.81
2.68
−0.93
0.51
Tax %
15.26%
21.24%
21.52%
26.12%
−3.23%
−35.29%
Net Profit
1.6
2.03
2.99
1.97
−0.9
0.69
EPS (₹)
1.36
1.52
2.24
1.09
−0.5
0.38

Profit & Loss

₹ Cr
ONYX profit and loss, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
44.86
39.49
53.75
61.95
69.47
Expenses
39.09
34.99
45.36
51.57
66.06
Operating Profit
5.77
4.5
8.39
10.38
3.41
OPM %
12.86%
11.4%
15.61%
16.76%
4.91%
Other Income
0.12
0.11
0.13
1.17
0.44
Interest
0.65
0.57
2.16
2.02
1.22
Depreciation
1.45
1.49
1.87
3.05
3.05
PBT
3.79
2.55
4.49
6.48
−0.42
Tax %
11.61%
27.45%
19.15%
23.46%
−50%
Net Profit
3.35
1.84
3.63
4.95
−0.21
EPS (₹)
2.84
1.56
2.72
2.73
−0.12
Div. Payout %
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
ONYX balance sheet, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.9
5.9
13.32
18.13
18.13
Reserves
10.47
12.3
11.97
37.49
37.28
Borrowings
12.25
29.23
30.78
12.46
15.17
Other Liabilities
8.22
11.3
18.07
23.17
24.58
Total Liabilities
36.84
58.73
74.14
91.25
95.16
Fixed Assets
17.23
42.5
43.48
40.9
39.16
CWIP
4.02
0
0
0
3.68
Investments
0
0
0
0
0
Other Assets
15.59
16.23
30.66
50.35
52.32
Total Assets
36.84
58.73
74.14
91.25
95.16

Cash Flow

₹ Cr
ONYX cash flow, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.49
1.96
1.52
1.42
−1.49
Investing
−5.78
−22.68
−3.15
0.66
−4.58
Financing
5.2
16.43
3.09
5.07
1.5
Net Cash Flow
−0.09
−4.3
1.46
7.15
−4.57
Free Cash Flow
−5.3
−20.78
−1.7
1.91
−6.48
CFO/EBITDA
8
44
18
14
−44

Ratios

ONYX financial ratios, annual
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68.51
46.95
104
119
144
Inventory Days
41.98
110
92.94
150
99.2
Days Payable
59.46
120
141
156
125
Cash Conversion Cycle
51.03
36.71
56.48
113
119
Working Capital Days
35.72
−52.22
37.62
87.49
77.29
ROCE %
—
8.23%
12.85%
12.16%
1.15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Onyx Biotec insights

51 extracted metrics across FY22–FY26.

Shareholding Pattern

As of Sep 2026

  • Public 50.96%
  • Promoters 41.74%
  • Others 4.68%
  • DIIs 2.39%
  • FIIs 0.22%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Onyx Biotec

What does Onyx Biotec Ltd do?
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model
Where is Onyx Biotec Ltd (ONYX) listed?
Onyx Biotec Ltd trades as ONYX on the NSE.
Which sector does Onyx Biotec Ltd belong to?
Onyx Biotec Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Onyx Biotec Ltd?
Over the last 52 weeks Onyx Biotec Ltd has traded between ₹24.2 and ₹49.65 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Onyx Biotec Ltd?
Onyx Biotec Ltd reported a return on equity of -0.38%. Its debt-to-equity ratio is 0.27.

Company Information

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model

Website onyxbiotec.com
Listed 22 Nov 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ONYX.md for Onyx Biotec Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month